Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA:688091)

China flag China · Delayed Price · Currency is CNY
53.88
+2.38 (4.62%)
Mar 10, 2026, 2:04 PM CST
30.14%
Market Cap 10.58B
Revenue (ttm) 317.08M
Net Income (ttm) 64.13M
Shares Out 205.43M
EPS (ttm) 0.31
PE Ratio 166.13
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,441,152
Average Volume 3,834,145
Open 52.15
Previous Close 51.50
Day's Range 51.51 - 53.95
52-Week Range 36.50 - 83.60
Beta -0.37
RSI 50.39
Earnings Date Apr 28, 2026

About SHA:688091

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was founded in 2009 and is headquartered in Shanghai, China. [Read more]

Sector Healthcare
Founded 2009
Employees 415
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688091
Full Company Profile

Financial Performance

In 2025, SHA:688091's revenue was 317.08 million, an increase of 82.72% compared to the previous year's 173.53 million. Earnings were 64.13 million, an increase of 819.42%.

Financial Statements

News

There is no news available yet.